Bristol-myers Squibb Compnay

Arsenal Biosciences, Inc.

Natalie Bezman

Alan J Korman

Guodong Chen

Richard Y Huang

Ginger Chao Rakestraw

Karla Ann Henning

Shrikant Deshpande

Christine Bee

Vangipuram S Rangan

Xiang Shao

Amy D Jhatakia

Haichun Huang

Mohan Srinivasan

Pavel Strop

Robert F Graziano

Katherine Harris

Michelle Renee Kuhne

Aaron Cooper

Stephen Santoro

Anzhi Yao

Michelle Nguyen

John Gagnon

Harbani Kaur Malik Chaudhry

Omar Khan

Yiming Yin

Peter Sung Keun Lee

Gamze Ozlem Camdere

Adam Litterman

Nicole Allen

Jasper Williams

Ginger C Rakestraw

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

Provided herein are recombinant nucleic acids encoding chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX. Also provided are systems of chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX, cells expressing such proteins and shRNA, and methods of use thereof.

Immune cells having co-expressed shRNAS and logic gate systems

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Antibodies against MICA and/or MICB and uses thereof

Growing community of inventors

Foster City, CA, United States of America

Natalie Bezman